Abstract
Dopamine (1) is a key neurotransmitter whose impact on pharmacological processes is mediated by a family of dopamine receptors designated D1, D2, D3, D4, and D5. Various diseases and conditions such as schizophrenia, drug abuse, depression, restless leg syndrome, Parkinson’s disease (PD), and inflammatory diseases have been linked to aberrant D3 activity. Herein, we report a series of novel D3 ligands with improved solubility over our previous lead compound, MC25-41 (2).[Figure not available: see fulltext.]
Original language | English |
---|---|
Pages (from-to) | 446-461 |
Number of pages | 16 |
Journal | Medicinal Chemistry Research |
Volume | 31 |
Issue number | 3 |
DOIs | |
State | Published - Mar 2022 |
Keywords
- D dopamine receptor
- D dopamine receptor
- Dopamine